作者
Melina Peressini,Rosario García-Campelo,Bartomeu Massutí,Cristina Martí,Manuel Cobo,Vanesa Gutiérrez,Manuel Dómine,José Fuentes,Margarita Majem,Javier de Castro,Juan F. Córdoba,María P. Diz,Dolores Isla,Emilio Esteban,Enric Carcereny,Laia Vilà,Alberto Moreno-Vega,Silverio Ros,Amaia Moreno,Francisco J. García,G. Huidobro,Carlos Aguado,Víctor Cebey-López,Javier Valdivia,Ramón Palmero,P. Lianes,Marta López-Brea,Óscar Juan,Mariano Provencio,Edurne Arriola,Javier Baena,Mercedes Herrera,Helena Bote,Magdalena Molero,Vera Adradas,Santiago Ponce-Aix,Ángel Nuñez-Buiza,Álvaro C. Ucero,Susana Hernández,Fernando López-Rı́os,Esther Conde,Luis Paz‐Ares,Jon Zugazagoitia
摘要
Transcriptomic subtyping holds promise for personalized therapy in extensive-stage small cell lung cancer (ES-SCLC). In this study, we aimed to assess intratumoral transcriptomic subtype diversity and to identify biomarkers of long-term chemoimmunotherapy benefit in human ES-SCLC.